Sortina Pharma has received funding from Vinnova to test our lead sortilin inhibitors in an intracranial glioblastoma model at the Centre for Preclinical Cancer Treatment (PCT), Uppsala University.
The results will help us select a candidate for further development.
Glioblastoma is the most common and most aggressive primary brain tumour in adults, and standard treatment has changed little in two decades.
The grant comes from Vinnova’s call supporting small and medium-sized companies in using Sweden’s life science infrastructure. Access to a facility like PCT is exactly what a company our size cannot build on its own.
More more info here